MX2023007297A - 3-fluoro-but-3-enamidas ramificadas macrociclicas como inhibidores de mcl-1. - Google Patents

3-fluoro-but-3-enamidas ramificadas macrociclicas como inhibidores de mcl-1.

Info

Publication number
MX2023007297A
MX2023007297A MX2023007297A MX2023007297A MX2023007297A MX 2023007297 A MX2023007297 A MX 2023007297A MX 2023007297 A MX2023007297 A MX 2023007297A MX 2023007297 A MX2023007297 A MX 2023007297A MX 2023007297 A MX2023007297 A MX 2023007297A
Authority
MX
Mexico
Prior art keywords
mcl
inhibitors
enamides
macrocyclic
fluoro
Prior art date
Application number
MX2023007297A
Other languages
English (en)
Inventor
Frederik Jan Rita Rombouts
Meng- Yang HSIAO
Soufyan Jerhaoui
Michel Surkyn
Matthieu Dominique Jouffroy
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX2023007297A publication Critical patent/MX2023007297A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/20—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se relaciona con agentes farmacéuticos de la Fórmula (I) útiles para terapia y/o profilaxis en un sujeto, composición farmacéutica que comprende tales compuestos, y su uso como inhibidores de MCL-1, útiles para tratar enfermedades tales como cáncer.
MX2023007297A 2020-12-17 2021-12-16 3-fluoro-but-3-enamidas ramificadas macrociclicas como inhibidores de mcl-1. MX2023007297A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20214807 2020-12-17
PCT/EP2021/086192 WO2022129331A1 (en) 2020-12-17 2021-12-16 Macrocyclic branched 3-fluoro-but-3-enamides as inhibitors of mcl-1

Publications (1)

Publication Number Publication Date
MX2023007297A true MX2023007297A (es) 2023-07-04

Family

ID=73855218

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023007297A MX2023007297A (es) 2020-12-17 2021-12-16 3-fluoro-but-3-enamidas ramificadas macrociclicas como inhibidores de mcl-1.

Country Status (9)

Country Link
US (1) US20240083890A1 (es)
EP (1) EP4263558A1 (es)
JP (1) JP2023554070A (es)
KR (1) KR20230121806A (es)
CN (1) CN116670141A (es)
AU (1) AU2021404501A1 (es)
CA (1) CA3200704A1 (es)
MX (1) MX2023007297A (es)
WO (1) WO2022129331A1 (es)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3474B1 (ar) 2014-08-29 2020-07-05 Amgen Inc مشتقات تيتراهيدرونافثالين التي تثبط بروتين mcl-1
WO2017147410A1 (en) 2016-02-25 2017-08-31 Amgen Inc. Compounds that inhibit mcl-1 protein
JP6453507B2 (ja) 2017-03-30 2019-01-16 アムジエン・インコーポレーテツド Ｍｃｌ−１タンパク質を阻害する化合物
EP3668878A1 (en) 2017-08-18 2020-06-24 Amgen Inc. Compounds that inhibit mcl-1 protein
EP3676270A1 (en) 2017-08-29 2020-07-08 Amgen Inc. Macrocyclic compounds that inhibit mcl-1 protein
MA54985A (fr) 2018-03-05 2021-12-29 Amgen Inc Pharmacophores d'acide alpha-hydroxy phénylacétique ou antagonistes de la protéine bio-isostère mcl-1
MX2020012137A (es) 2018-05-14 2021-01-29 Gilead Sciences Inc Inhibidores de mcl-1.
JP2022506973A (ja) 2018-11-09 2022-01-17 プレリュード セラピューティクス，インコーポレイティド 骨髄性細胞白血病－１（ｍｃｌ－１）タンパク質の阻害剤としてのスピロ－スルホンアミド誘導体
CA3144558A1 (en) * 2019-07-09 2021-01-14 Janssen Pharmaceutica Nv Macrocyclic spirocycle derivatives as mcl-1 inhibitors
US20230212191A1 (en) 2020-04-16 2023-07-06 Prelude Therapeutics, Incorporated Spiro-sulfonimidamide derivatives as inhibitors of myeloid cell leukemia-1 (mcl-1) protein

Also Published As

Publication number Publication date
KR20230121806A (ko) 2023-08-21
EP4263558A1 (en) 2023-10-25
CA3200704A1 (en) 2023-06-23
US20240083890A1 (en) 2024-03-14
CN116670141A (zh) 2023-08-29
WO2022129331A1 (en) 2022-06-23
JP2023554070A (ja) 2023-12-26
AU2021404501A1 (en) 2023-08-03

Similar Documents

Publication Publication Date Title
MX2022000390A (es) Derivados macrociclicos espirociclicos como inhibidores de mcl-1.
MX2021006026A (es) Pirimidina y derivado heterociclico de nitrogeno de cinco miembros, metodo de preparacion y usos medicos de los mismos.
MX2022015813A (es) 2-amino-3-fluoro-but-3-enamidas macrociclicas como inhibidores de mcl-1.
CR20230310A (es) Inhibidores de prmt5
MX2023000438A (es) Eter macrociclico que contiene derivados de indol como inhibidores de mcl-1.
MX2021015770A (es) Inhibidores macrociclicos de mcl-1.
MX2020006219A (es) Derivados de 1-piperidinocarbonilmetil)-2-oxopiperazina para tratar cancer.
PH12018501567A1 (en) New substituted cyanoindoline derivatives as nik inhibitors
SG10201810401RA (en) Pharmaceutical combinations for treating cancer
MX2021012501A (es) Inhibidores de complejo represivo polycomb 2 (prc2).
MX2023006145A (es) Inhibidores de prmt5 novedosos.
MX2022005298A (es) Compuestos intermediarios de sintesis de inhibidores de a2a.
MX2019006843A (es) Inhibidor de cdk4/6.
ZA202201364B (en) Deuterated compounds for use in the treatment of cancer
MX2023009222A (es) Inhibidores tricíclicos-amido-bicíclicos de prmt5.
MX2022006180A (es) Derivados macrociclicos de sulfonilo como inhibidores de mcl-1.
MX2023007297A (es) 3-fluoro-but-3-enamidas ramificadas macrociclicas como inhibidores de mcl-1.
MX2022006179A (es) Derivados macrociclicos de indol como inhibidores de mcl-1.
MX2022015005A (es) Derivados de 7-pirazol-5-il-indol macrociclicos como inhibidores de mcl-1.
ZA202201499B (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
MX2023003516A (es) Inhibidores no covalentes de la cinasa dependiente de ciclina 7 (cdk7).
MX2022010299A (es) Derivados macrocíclicos de indol como inhibidores de mcl-1.
MX2023007291A (es) Derivados de 4-(pirazol-5-il)-indol macrociclicos ramificados como inhibidores de mcl-1.
MX2022011565A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2022016004A (es) Desderivados de 7-(pirazol-5-il)-indol macrociclicos enlazados a n como inhibidores de mcl-1.